NephJC Shorts

Nephrology produces far more new studies each week than NephJC can realistically cover in its twice‑monthly full reviews. That’s why we’re introducing NephJC Short- quick, sharp summaries of notable papers that caught the editorial team’s attention. Suggestions welcome, and feedback too.

🩳Read more on the blog post describing this initiative.

Upcoming NephJC Shorts

Nondialyzable versus Dialyzable Beta-Blockers in Hemodialysis (Etemadi A et al, JASN, 2026)

Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial (Heerspink HJL et al, Lancet, 2026)
Vasopressors or Fluids in Early Septic Shock (ARISE Fluids investigators, NEJM, 2026)
Increasing Plasma Sodium with Tolvaptan Under Regulated Water Intake (Sweis NW et al, Am J Physiol Renal Physiol. 2026)
Randomized Trial of Dietary Nitrate Supplementation in CKD Pregnancy (ORCHARD-BEET) (Smith P et al, KI reports, 2026)

Blog

Dietary nitrate supplementation in CKD pregnancy

First trial in pregnancy and CKD after 30 years - aiming to test feasibility of nitrate administration in pregnant women with CKD

Is this the end of the beta-blocker debate in hemodialysis?

Non-dialyzable beta-blockers showed lower MACE, but the study was observational and shaped by regional prescribing habits that may hide confounding factors.

NephJC Short: 24-Month Iptacopan eGFR Data in IgA Nephropathy

Iptacopan decreases proteinuria, now we get the 24-month eGFR data in patients with IgA Nephropathy.

Finerenone across the proteinuric CKD spectrum

Cristina Popa dissects the FIND-CKD extras: GN subgroup and INFINITY analysis

NephJC Short: When BAFF Meets APRIL: Telitacicept in IgA Nephropathy (TELIGAN trial)

Does Dual BAFF/APRIL Blockade with Telitacicept Reduce Proteinuria in Persistent Proteinuric IgA Nephropathy?

Can we predict who benefits from steroids in IgAN? The PRED-IgAN Study

A post hoc analysis from TESTINg tries to answer this question

NephJC Short: The map and the territory: what measured GFR teaches us about our estimates

Is measured GFR more accurate than eGFR for forecasting adverse outcomes?

NephJC Short: Bayesian leash: How a prior walked the Tigris across the finish line

Can polymyxin B hemadsorption truly shift the fate of septic shock, or is the outcome already written?

NephJC Short: Finerenone in Type I Diabetic CKD - Fine, but doesn’t reach the Finish Line? FINEONE

In type 1 diabetes is finerenone helpful to reduce proteinuria?

NephJC Short: The Push Trial

Water, water everywhere. Can a wink, a nudge and a push increase water intake to decrease kidney stone formation?

Dialysis delay at what cost? Protein restriction as a distraction in the age of GDMT

The NephJC shorts on cost-efficiency of low-protein diets and ketoanalogues as a distraction from CKD-relevant therapies in the 21st century… wait, only if the comparator wouldn’t be dialysis.